Grace Dy, MD, from the Roswell Park Cancer Institute, discusses the therapeutic index of targeted therapies and conventional cytotoxics.
Grace Dy, MD, Associate Professor, Department of Medicine, Roswell Park Cancer Institute, discusses the therapeutic index of targeted therapies and conventional cytotoxics.
As the oncology community has learned over time, the idea that the therapeutic index of targeted therapies as a group is much better than cytotoxics may not be entirely true. Certain toxicities such as myelosuppression or hair loss may not be as common in patients treated with targeted therapies.
Targeted therapies have shown that they can affect multiple organs in the body as some drugs inhibit targets found in normal tissues. This causes an entire spectrum of side effects that are difficult to anticipate. Targeted therapies make treatment much more interesting and challenging for a medical oncologist, Dy says.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More